PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTC Market: AVXT.OB) announces the appointment of Isabelle Fourthin, MD as Chief Medical Officer for Europe, Middle East and Africa (EMEA). Dr. Fourthin will be responsible for recruiting and overseeing European clinical sites for AVAX’s phase III registration study of MVax®, its autologous, hapten-modified melanoma vaccine, and for new indications for the AC-Vaccine technology as they develop.
